The metabolic breakdown of pharmaceuticals by living organisms, often mediated by specialised enzyme systems, is known as drug metabolism. More specifically, xenobiotic metabolism refers to the set of metabolic pathways that alter the chemical structure of xenobiotics, which are substances foreign to an individual's normal biochemistry, like any drug or poison. The term comes from the Greek words xenos, meaning "stranger," and biotic, meaning "related to living beings." These bio transformational routes, which are found in all significant groupings of species, are thought to have existed long ago. These processes frequently cleanse harmful substances (although in some cases the intermediates in xenobiotic metabolism can themselves cause toxic effects). The field of pharmacokinetics investigates how drugs are metabolised. An essential component of pharmacology and medicine is the metabolism of pharmacological medicines. For instance, a drug's pharmacologic action's duration and potency are determined by its rate of metabolism. Multidrug resistance in infectious illnesses and cancer treatment are also influenced by drug metabolism, and dangerous drug interactions are frequently caused by the activities of certain medications as substrates or inhibitors of enzymes involved in xenobiotic metabolism. The xenobiotic metabolism of microorganisms determines whether a contaminant will be broken down during bioremediation or stay in the environment, making these pathways crucial in environmental research. In agriculture, the xenobiotic metabolism enzymes, in particular the glutathione S-transferases, are crucial because they may result in pesticide and herbicide resistance.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia